glp 1 elevated liver enzymes Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide Receptor Agonists in Nonalcoholic Fatty Disease Potential effects of GLP-1 and

Because GLP-2 acts through subepithelial myofibroblasts, which are the same cell population implicated in intestinal fibrogenesis, the risk-benefit profile of GLP-2 agonism may differ substantially between mucosal UC, inflammatory ileal CD, and stricturing or penetrating CD phenotypes, and this phenotypic stratification should be a required feature of future trial design

Succinic semialdehyde (4-oxobutanoate) acts as a suitable substrate analog` as this molecule only lacks the 3-hydroxy group of MSA (3-hydroxy-4-oxobutanoate) which could be added in silico

Dialysis therapy Next XVII

Dyatlova N et al

PMID: 36351210